ALCOX — Nicox SA Share News
0.000.00%
Last trade - 00:00- €32.43m
- €28.69m
- €16.77m
Brief: Nicox FY Net Revenue Up At 8.9 Million Euros
Brief: Nicox's Licensee Bausch And Lomb Launches Vyzulta In Mexico
Brief: Nicox Expects Significant Milestones In 2021
Brief: Nicox's Partner Ocumension Therapeutics Initiates Zerviate Phase 3 Clinical Trial In China
Brief: Nicox’S Licensee Bausch + Lomb Secures Approval Of VYZULTA In Colombia
Brief: Nicox Initiates Phase 2B Trial Of NCX 4251
Brief: Nicox’S Partner Fera Pharmaceuticals To Investigate Naproxcinod As Covid-19 Adjuvant Treatment
Brief: Nicox Raises EUR 15 Million In Private Placement
Brief: Ocumension Therapeutics Initiation Of Second Phase 3 Clinical Trial Of OT-301 In U.S.
Brief: Nicox Initiates Second Phase 3 Trial Of NCX 470 In Glaucoma
Brief: Nicox Granted Patent For NCX 470, Extending Exclusivity In Europe To 2039
Brief: Nicox: NCX 470 Receives Approval By Chinese Authorities For Start Of Mont Blanc Phase 3 Trial
Brief: Nicox Selects New Drug Candidate For In-House Development Program
Brief: Nicox Q3 Net Revenue At EUR 0.8 Million
Brief: Nicox Announces Plans For NCX 4251 Phase 2 Trial In Blepharitis
Brief: Nicox: Mississippi Phase 2 Trial For NCX 4251 To Start In Dec 2020
Brief: Nicox Announces Vyzulta Is Now Approved In 7 Countries
Brief: Nicox Selects 0.1% NCX 470 Dose In Mont Blanc Phase 3 Glaucoma Trial
Brief: Nicox: Zerviate Receives Approval To Carry Out Phase III Clinical Trial In China